MXPA04004501A - Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos. - Google Patents

Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos.

Info

Publication number
MXPA04004501A
MXPA04004501A MXPA04004501A MXPA04004501A MXPA04004501A MX PA04004501 A MXPA04004501 A MX PA04004501A MX PA04004501 A MXPA04004501 A MX PA04004501A MX PA04004501 A MXPA04004501 A MX PA04004501A MX PA04004501 A MXPA04004501 A MX PA04004501A
Authority
MX
Mexico
Prior art keywords
lower alkyl
difluoro
tetrahydro
halogeno
optionally substituted
Prior art date
Application number
MXPA04004501A
Other languages
English (en)
Inventor
Saitor Chikashi
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of MXPA04004501A publication Critical patent/MXPA04004501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen derivados de 4,4-fifluoro-1,2,3,4-tetrahidro-5H-1-benzazepina representados por la formula general (I), los cuales tienen excelente actividad agonista del receptor V2 de arginina vasopresina y son utiles en el tratamiento de diabetes insipida central y/o nocturia; en donde R1 es -OH, -O-alquilo inferior, o amino sustituido opcionalmente; R2 es alquilo inferior que puede ser sustituido con uno o mas halogenos, o halogeno; uno R3 y R4 es -H, alquilo inferior o halogeno, y el otro es amino ciclico no aromatico sustituido opcionalmente, o amino ciclico aromatico sustituido opcionalmente y R5: -H, alquilo inferior o halogeno.
MXPA04004501A 2001-11-16 2002-11-13 Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos. MXPA04004501A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001350909 2001-11-16
JP2002252931 2002-08-30
PCT/JP2002/011842 WO2003042181A1 (fr) 2001-11-16 2002-11-13 Derives de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine, ou sels desdits derives

Publications (1)

Publication Number Publication Date
MXPA04004501A true MXPA04004501A (es) 2004-08-11

Family

ID=26624548

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004501A MXPA04004501A (es) 2001-11-16 2002-11-13 Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos.

Country Status (17)

Country Link
US (1) US7169772B2 (es)
EP (1) EP1445253B1 (es)
JP (1) JP4075064B2 (es)
KR (1) KR100632882B1 (es)
CN (1) CN1323076C (es)
AT (1) ATE438626T1 (es)
AU (1) AU2002349773B2 (es)
BR (1) BR0214224A (es)
CA (1) CA2464069A1 (es)
DE (1) DE60233251D1 (es)
ES (1) ES2327620T3 (es)
HU (1) HUP0402235A2 (es)
MX (1) MXPA04004501A (es)
NO (1) NO20042497L (es)
PL (1) PL369999A1 (es)
RU (1) RU2268882C1 (es)
WO (1) WO2003042181A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP2006508339A (ja) 2002-09-20 2006-03-09 プロメガ　コーポレイション シトクロムｐ４５０活性を測定するための発光を利用する方法およびプローブ
WO2004047730A2 (en) * 2002-11-21 2004-06-10 New York Blood Center Compounds for inhibition of hiv infection by blocking hiv entry
ATE512951T1 (de) 2003-04-28 2011-07-15 Astellas Pharma Inc 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivat oder salz davon
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2006130551A2 (en) 2005-05-31 2006-12-07 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
EP1935986B1 (en) 2005-05-31 2014-04-16 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
ES2531621T3 (es) 2005-07-22 2015-03-18 Mochida Pharmaceutical Co., Ltd. Derivado de heterociclidenacetamida novedoso
JP5164510B2 (ja) * 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
TW200835502A (en) 2006-12-26 2008-09-01 Daiichi Sankyo Co Ltd Thiazepine derivatives
US20100016285A1 (en) * 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
PE20081692A1 (es) 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
US8227500B2 (en) 2007-04-11 2012-07-24 Kissei Pharmaceutical Co., Ltd. 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2009143356A1 (en) * 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
DK2860175T3 (da) 2012-06-11 2018-01-29 Tacurion Fremgangsmåde til fremstilling af 4,4,7-trifluor-1,2,3,4-tetrahydro-5h-1-benzazepin-forbindelse og intermediat til syntese deraf
RU2642783C2 (ru) * 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
CN105310978A (zh) * 2014-08-04 2016-02-10 李峰 一种含有活性成分盐酸考尼伐坦的药物组合物及其制剂
CN112079826B (zh) * 2020-09-17 2022-07-29 广州中医药大学(广州中医药研究院) 一类甾体合成酶抑制剂及其治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1039999A (zh) * 1988-07-30 1990-02-28 刘晓非 多层复合装饰板及制作方法
TW270927B (es) 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
PL182011B1 (en) * 1993-08-26 2001-10-31 Yamanouchi Pharma Co Ltd Benzazepine derivative, pharmaceutic composition and intermediate compounds
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.

Also Published As

Publication number Publication date
CN1585752A (zh) 2005-02-23
KR100632882B1 (ko) 2006-10-13
JPWO2003042181A1 (ja) 2005-03-10
HUP0402235A2 (hu) 2005-02-28
AU2002349773B2 (en) 2007-12-13
US20050004103A1 (en) 2005-01-06
RU2004118063A (ru) 2006-01-10
BR0214224A (pt) 2004-09-21
RU2268882C1 (ru) 2006-01-27
CN1323076C (zh) 2007-06-27
ES2327620T3 (es) 2009-11-02
US7169772B2 (en) 2007-01-30
EP1445253A1 (en) 2004-08-11
PL369999A1 (en) 2005-05-16
KR20050044401A (ko) 2005-05-12
EP1445253B1 (en) 2009-08-05
EP1445253A4 (en) 2005-11-16
WO2003042181A1 (fr) 2003-05-22
NO20042497L (no) 2004-07-21
JP4075064B2 (ja) 2008-04-16
CA2464069A1 (en) 2003-05-22
ATE438626T1 (de) 2009-08-15
DE60233251D1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
MXPA04004501A (es) Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos.
HK1079191A1 (en) Pleuromutilin derivatives as antimicrobbials
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
NO20070984L (no) Dihydropterididinon infusjonslosning som har en lang lagringstid
YU83602A (sh) Derivati fenilglicina
IS7325A (is) alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar
AP2002002637A0 (en) Novel piperazine
AR045782A2 (es) Derivados de piperidina que tienen actividad farmaceutica
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
HK1048474A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones.
NO20025893D0 (no) Veksthormon sekretagoga
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
AR028705A1 (es) Bis-arilsulfonas
EA200200108A1 (ru) Производные стрептограминов, способ их получения и композиции на их основе
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ATE272048T1 (de) Aminosäuren mit polycyclischer struktur als pharmaka
DE60104435D1 (en) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
CO5180541A1 (es) Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
ATE286887T1 (de) Antibakterielle mittel
EA200201234A1 (ru) Производные сульфонамида
DE69816832D1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
MXPA02011553A (es) N-hidroxiformamidas sustituidas por biciclico heterobiciclilmetansulfonilamino.
EA200000946A1 (ru) Кристаллическая форма пароксетина
BR9406996A (pt) Enanciômero processo para preparar o mesmo processo para ciclizar um composto e composto intermediário

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration